Shukra Pharmaceut.
Ticker > Company >

Shukra Pharmaceut. share price

Shukra Pharmaceuticals Ltd.

BSE: 524632 SECTOR: Pharmaceuticals & Drugs  41.69 K   98   5

29.33
+0.13 (0.45%)
BSE: 24 Jun 4:00 PM

Price Summary

Today's High

₹ 29.99

Today's Low

₹ 28.5

52 Week High

₹ 65.26

52 Week Low

₹ 13.22

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 1289.39 Cr.

Enterprise Value

₹ 1281.45 Cr.

No. of Shares

43.96 Cr.

P/E

58.48

P/B

14.51

Face Value

₹ 1

Div. Yield

0.03 %

Book Value (TTM)

₹  2.02

CASH

₹ 12.12 Cr.

DEBT

₹ 4.18 Cr.

Promoter Holding

50.96 %

EPS (TTM)

₹  0.5

Sales Growth

-56.3%

ROE

15.9 %

ROCE

21.8%

Profit Growth

-48.35 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-56.3%
3 Year16.73%
5 Year22.43%

Profit Growth

1 Year-48.35%
3 Year133.65%
5 Year206.15%

ROE%

1 Year15.9%
3 Year27.25%
5 Year17.53%

ROCE %

1 Year21.8%
3 Year28.3%
5 Year18.24%

Debt/Equity

0.0665

Price to Cash Flow

162.83

Interest Cover Ratio

23.4182

CFO/PAT (5 Yr. Avg.)

0.43090060255368

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2026 50.96 0.00
Dec 2025 50.96 0.00
Sep 2025 50.96 0.00
Jun 2025 50.96 0.00
Mar 2025 50.96 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 16.7337395079862% for the Past 3 years.
  • Company has been maintaining healthy ROE of 27.2539333333333% over the past 3 years.
  • Company has been maintaining healthy ROCE of 28.2980333333333% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 23.4182.
  • The Company has been maintaining an effective average operating margins of 20.23634% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -114.741 days.
  • Company has a healthy liquidity position with current ratio of 3.7855.
  • The company has a high promoter holding of 50.96%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 4.7249543439362.

 Limitations

  • Company has high debtor days of 186.3788.
  • The company is trading at a high PE of 58.48.
  • The company is trading at a high EV/EBITDA of 38.7358.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Net Sales 13.27 5.39 5.88 39.14 6.3
Total Expenditure 5.95 4.07 6.3 12 5.62
Operating Profit 7.32 1.32 -0.42 27.14 0.69
Other Income 1.47 1.11 1.71 0.82 0.95
Interest 0.27 0.27 0.29 0.28 0.26
Depreciation 0.94 0.79 0.81 0.84 1.01
Exceptional Items 0 0 0 0 0
Profit Before Tax 7.57 1.37 0.2 26.83 0.37
Tax 2.18 0.34 -2.18 6.47 2.09
Profit After Tax 5.39 1.03 2.38 20.37 -1.73
Adjusted EPS (Rs) 0.12 0.02 0.05 0.47 -0.04

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 11.2 20.49 58.83 74.57 32.59
Total Expenditure 9.75 17.6 53.47 55.17 19.86
Operating Profit 1.44 2.89 5.36 19.4 12.73
Other Income 0.36 0.08 1.2 2.82 4.21
Interest 0.03 0.29 0.28 0.29 0.59
Depreciation 1.47 1.66 1.84 2.05 3
Exceptional Items -0.2 0 0 0 0
Profit Before Tax 0.1 1.02 4.44 19.88 13.34
Tax -0.09 0.27 0.04 1.35 3.76
Net Profit 0.19 0.75 4.41 18.54 9.58
Adjusted EPS (Rs.) 0.01 0.02 0.28 0.42 0.22

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 1.57 1.57 3.91 10.95 43.79
Total Reserves 14.03 14.78 21.38 46.69 19.05
Borrowings 9.77 3.13 3.77 2.66 3.11
Other N/C liabilities 3.2 3.26 3.4 3.39 3.54
Current liabilities 7.03 12.38 42.51 14.15 17.28
Total Liabilities 35.61 35.11 74.97 77.84 86.77
Assets
Net Block 17.69 17.58 20.23 19.94 19.4
Capital WIP 1.66 1.66 1.66 1.66 1.95
Intangible WIP 0 0 0 0 0
Investments 0.19 0 0 0 0
Loans & Advances 0 0 0 0 0
Other N/C Assets 0 0 0 0 0
Current Assets 16.06 15.87 53.07 56.23 65.43
Total Assets 35.61 35.11 74.97 77.84 86.77
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 0.1 1.02 4.44 19.88 13.34
Adjustment 1.44 1.91 1.6 1.55 2.12
Changes in Assets & Liabilities -1 5.5 -2.62 -26.01 -3.78
Tax Paid 0 -0.44 -0.25 -0.62 -3.76
Operating Cash Flow 0.54 7.99 3.17 -5.2 7.92
Investing Cash Flow -1.89 -1.53 -4.43 -1.2 -1.26
Financing Cash Flow 1.74 -6.68 4.94 12.41 -4.52
Net Cash Flow 0.38 -0.21 3.68 6.01 2.14

Corporate Actions

Investors Details

PARTICULARS Mar 2025% Jun 2025% Sep 2025% Dec 2025% Mar 2026%
promoters 50.96 50.96 50.96 50.96 50.96
anar jayeshbhai patel 1.00 1.00 1.00 1.00 1.00
anar project private limi... 18.78 18.78 18.78 18.78 18.78
dakshesh rameshchandra ... 1.00 1.00 1.00 1.00 1.00
navkar surgical gujarat 11.78 11.78 11.78 11.78 11.78
parshva texchem india pr... 17.17 17.17 17.17 17.17 17.17
payal sujay mehta 0.52 0.52 0.52 0.52 0.52
sujay jyotindra mehta 0.71 0.71 0.71 0.71 0.71
PARTICULARS Mar 2025% Jun 2025% Sep 2025% Dec 2025% Mar 2026%
investors 49.04 49.04 49.04 49.04 49.04
llp 0.12 0.02 0.25 0.05 0.01
renuka yogesh parikh 19.18 19.18 19.18 19.18 19.18
yogesh biharilal parikh 19.18 19.18 19.18 19.18 19.18

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Shukra Pharmaceuticals informs about closure of trading window 20 Mar, 2:47 PM Shukra Pharmaceuticals informs about separate meeting of independent directors 6 Mar, 5:22 PM Shukra Pharma - Quaterly Results 5 Feb, 12:00 AM Shukra Pharmaceuticals enters into MoU with Borns Medical Robotics 5 Jan, 3:51 PM Shukra Pharma gets Univlabs Technologies’ nod to sell laparoscopic sets in Gujarat 22 Dec, 2:42 PM Shukra Pharmaceuticals informs about press release 5 Dec, 1:20 PM Shukra Pharmaceuticals gets authorized distributor certificate from Integra Medical Devices India 3 Dec, 4:44 PM Shukra Pharmaceuticals informs about notice of postal ballot 3 Dec, 3:58 PM Shukra Pharmaceuticals partners with Wockhardt 11 Sep, 3:20 PM Shukra Pharmaceuticals bags contract from HSCC (India) 29 Aug, 9:30 AM Shukra Pharma - Quaterly Results 13 Aug, 3:49 PM Shukra Pharma - Quaterly Results 13 Aug, 3:49 PM Shukra Pharma - Quaterly Results 13 Aug, 3:49 PM Shukra Pharmaceuticals executes service agreement with APITCO 28 Jul, 12:12 PM Shukra Pharmaceuticals informs about grant of distributorship rights 21 Jul, 5:23 PM Shukra Pharmaceuticals inaugurates four new branch offices 10 Jul, 12:00 PM Shukra Pharmaceuticals informs about compliance certificate 5 Jul, 1:45 PM Shukra Pharma - Quaterly Results 14 Feb, 4:53 PM Shukra Pharma - Quaterly Results 14 Feb, 4:53 PM Shukra Pharma - Quaterly Results 12 Aug, 6:39 PM Shukra Pharma - Quaterly Results 12 Aug, 6:39 PM Shukra Pharmaceuticals informs about disclosure 5 Apr, 4:53 PM Shukra Pharmaceuticals submits scrutinizer’s report 5 Apr, 3:51 PM Shukra Pharmaceuticals informs about outcome of postal ballot 5 Apr, 3:47 PM Shukra Pharma - Quaterly Results 12 Feb, 5:46 PM Shukra Pharma - Quaterly Results 12 Feb, 5:46 PM Shukra Pharmaceuticals informs about notice of postal ballot 28 Nov, 4:30 PM Shukra Pharmaceuticals informs about disclosure 13 Oct, 2:36 PM Shukra Pharmaceuticals informs about compliances-certificate 7 Oct, 2:13 PM Shukra Pharmaceuticals informs about press release 24 Apr, 2:55 PM Shukra Pharmaceuticals informs about newspaper publication 17 Mar, 5:07 PM Shukra Pharmaceuticals submits disclosure 11 Mar, 12:13 PM Shukra Pharmaceuticals informs about newspaper publication 6 Dec, 5:30 PM Shukra Pharmaceuticals informs about outcome of board meeting 2 Sep, 11:41 AM Shukra Pharmaceuticals informs about board meeting intimation 27 Aug, 4:31 PM Shukra Pharma - Quaterly Results 6 Aug, 3:43 PM Shukra Pharma - Quaterly Results 6 Aug, 3:43 PM Shukra Pharma - Quaterly Results 6 Aug, 3:43 PM Shukra Pharmaceutical informs about board meeting 23 Jul, 3:41 PM Shukra Pharma - Quaterly Results 12 Feb, 3:42 PM Shukra Pharmaceuticals informs about AGM 23 Sep, 2:57 PM Shukra Pharmaceuticals informs about newspaper publication 19 Nov, 11:08 AM

Shukra Pharmaceut. Stock Price Analysis and Quick Research Report. Is Shukra Pharmaceut. an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Shukra Pharmaceut.. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Shukra Pharmaceut. has a PE ratio of 58.4845463609172 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Shukra Pharmaceut. has ROA of 11.6339% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Shukra Pharmaceut. has a Current ratio of 3.7855.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Shukra Pharmaceut. has a ROE of 15.8961%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Shukra Pharmaceut. has a Debt to Equity ratio of 0.0665 which means that the company has low proportion of debt in its capital.

  • Sales growth: Shukra Pharmaceut. has reported revenue growth of -56.3014% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Shukra Pharmaceut. for the current financial year is 39.0633774507247%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Shukra Pharmaceut. is Rs 0.01 and the yield is 0.034%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Shukra Pharmaceut. is Rs 0.5015. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Shukra Pharmaceut. in Ticker for free. Also, one can get the intrinsic value of Shukra Pharmaceut. by using Valuation Calculators, which are available with a Finology ONE subscription. 

Shukra Pharmaceut. FAQs

Q1. What is Shukra Pharmaceut. share price today?
Ans: The current share price of Shukra Pharmaceut. is Rs 29.33.

Q2. What is the market capitalisation of Shukra Pharmaceut.?
Ans: Shukra Pharmaceut. has a market capitalisation of Rs 1289.38915252 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Shukra Pharmaceut.?
Ans: The PE ratio of Shukra Pharmaceut. is 58.4845463609172 and the P/B ratio of Shukra Pharmaceut. is 14.5090279495424, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Shukra Pharmaceut. share?
Ans: The 52-week high share price of Shukra Pharmaceut. is Rs 65.26, and the 52-week low share price of Shukra Pharmaceut. is Rs 13.22.

Q5. Does Shukra Pharmaceut. pay dividends?
Ans: Currently, Shukra Pharmaceut. pays dividends. Dividend yield of Shukra Pharmaceut. is around 0.034%.

Q6. What are the face value and book value of Shukra Pharmaceut. shares?
Ans: The face value of Shukra Pharmaceut. shares is Rs 1, while the book value per share of Shukra Pharmaceut. is around Rs 2.0215. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Shukra Pharmaceut.?
Ans: Shukra Pharmaceut. has a total debt of Rs 4.1767 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Shukra Pharmaceut.?
Ans: The ROE of Shukra Pharmaceut. is 15.8961% and ROCE of Shukra Pharmaceut. is 21.801%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Shukra Pharmaceut. a good buy for the long term?
Ans: The Shukra Pharmaceut. long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Shukra Pharmaceut. undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Shukra Pharmaceut. appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Shukra Pharmaceut.’s financials?
Ans: You can review Shukra Pharmaceut.’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Shukra Pharmaceut.
X